Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors

Authors

Brian C Shaffer, Memorial Sloan Kettering Cancer Center
Ramzi Abboud, Washington University School of Medicine in St. Louis
et al.

Journal

Journal of Clinical Oncology

Publication Date

10-1-2024

Volume

42

Issue

28

First Page

3277

Last Page

3286

Document Type

Open Access Publication

DOI

10.1200/JCO.24.00184

Rights and Permissions

Shaffer BC, Gooptu M, DeFor TE, Maiers M, Bolaños-Meade J, Abboud R, Briggs AD, Khimani F, Modi D, Newcomb R, Shpall EJ, Bupp C, Spellman SR, Stefanski HE, Shaw BE, Auletta JJ, Devine SM, Jimenez Jimenez AM, Al Malki MM. Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. J Clin Oncol. 2024 Oct;42(28):3277-3286. doi: 10.1200/JCO.24.00184. © 2024 by American Society of Clinical Oncology. Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Recommended Citation

Shaffer, Brian C; Abboud, Ramzi; and et al., "Post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis attenuates disparity in outcomes between use of matched or mismatched unrelated donors." Journal of Clinical Oncology. 42, 28. 3277 - 3286. (2024).
https://digitalcommons.wustl.edu/oa_4/4408

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.